Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza vaccine GSK2321138A · 3 trials · 1 indication
Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).
A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer \< 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).
Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. HI antibodies assessed were antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.
A seroconverted subject was a vaccinated subject who had either a pre-vaccination hemagglutination inhibition (HI) antibody titer \< 1:10 and a post-vaccination titer above or equal (\>=) 1:40, or a pre-vaccination HI antibody titer \>= 1:10 and at least a 4-fold increase in post-vaccination HI antibody titer. Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.
Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 3 influenza strains assessed were the FLU A/Brisbane/59/07 (H1N1), Flu A/Uruguay/716/07 (H3N2) and Flu B/Brisbane/60/08 Victoria (VICT).The POST results were the primary outcome variables.
| Arm | Type | Description |
|---|---|---|
| GSK2321138A 1 Group | EXPERIMENTAL | Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28. |
| Fluarix Group | ACTIVE_COMPARATOR | Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28. |
| GSK2604409A Group | ACTIVE_COMPARATOR | Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28. |
| GSK2321138A 2 Group | EXPERIMENTAL | Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28. |
| GSK2321138A Lot 1 Group | EXPERIMENTAL | Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm. |
| GSK2321138A Lot 2 Group | EXPERIMENTAL | Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm. |
| GSK2321138A Lot 3 Group | EXPERIMENTAL | Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm. |
| GSK2321138A Group | EXPERIMENTAL | Subjects aged between 18 and 47 months received the GSK2321138A. "Primed" subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the GSK2321138A-Primed Group) received 1 dose of GSK2321138A vaccine at Day 0. "Unprimed" subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the GSK2321138A-Unprimed Group) received 2 doses of GSK2321138A vaccine at Days 0 and 28. The GSK2321138A vaccine was administered intramuscularly in the deltoid of the right arm. |
| Name | Type | Description |
|---|---|---|
| Influenza vaccine GSK2321138A | BIOLOGICAL | intramuscular injections |
| FluarixTM | BIOLOGICAL | intramuscular injections |
| Influenza vaccine GSK2604409A | BIOLOGICAL | intramuscular injections |
| Fluarix™ | BIOLOGICAL | Intramuscular injection |
Inclusion Criteria: * Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol. * For non US countries: * \- Children, male or female, aged between 6 months and 17 years at the time of the first ...
GSK2321138A is an investigational influenza vaccine being developed by GSK plc for the prevention of influenza. It is a monoclonal antibody modality, though it is administered as a vaccine to generate an immune response against seasonal influenza strains. The vaccine is currently in Phase 3 clinical development.
GSK plc (ticker: GSK) is developing GSK2321138A. The company has conducted three clinical trials for this influenza vaccine candidate, all of which have been completed. GSK is a global biopharma company with a strong portfolio in vaccines and infectious disease treatments.
GSK2321138A is in Phase 3 clinical development for influenza. It has completed three trials, including two Phase 3 studies and one Phase 2 study. The vaccine is investigational and has not been approved by regulatory authorities. It remains in clinical development.
GSK2321138A has been studied in three completed trials: NCT00985790 (Phase 2, 599 children in Mexico), NCT01196988 (Phase 3, 3027 children in the US, Czechia, France, Germany, Philippines), and NCT01204671 (Phase 3, 4659 adults in the US, Germany, Romania, South Korea, Spain, Taiwan). All trials were randomized, double-blind, and active-controlled.
GSK2321138A is a vaccine designed to prevent influenza. It works by stimulating the immune system to produce antibodies against influenza viruses, providing protection against seasonal flu strains. The vaccine is administered to healthy individuals to induce immunity, though specific molecular targets are not disclosed.
GSK2321138A is a specific investigational influenza vaccine candidate developed by GSK. It is not marketed under alternative names in the available data. It is being studied as a seasonal influenza vaccine for children and adults, with trials conducted across multiple countries.